US20010000804A1 - Tissue decellularization - Google Patents

Tissue decellularization Download PDF

Info

Publication number
US20010000804A1
US20010000804A1 US09735522 US73552200A US2001000804A1 US 20010000804 A1 US20010000804 A1 US 20010000804A1 US 09735522 US09735522 US 09735522 US 73552200 A US73552200 A US 73552200A US 2001000804 A1 US2001000804 A1 US 2001000804A1
Authority
US
Grant status
Application
Patent type
Prior art keywords
tissue
decellularized
contacting
ml
leaflets
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US09735522
Inventor
Steven Goldstein
Kirby Black
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cryolife Inc
Original Assignee
Cryolife Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3683Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
    • A61L27/3695Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by the function or physical properties of the final product, where no specific conditions are defined to achieve this
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3604Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3683Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3683Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
    • A61L27/3687Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by the use of chemical agents in the treatment, e.g. specific enzymes, detergents, capping agents, crosslinkers, anticalcification agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, E.G. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/24Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices
    • A61F2/2412Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices with soft flexible valve members, e.g. tissue valves shaped like natural valves
    • A61F2/2415Manufacturing methods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L2430/00Materials or treatment for tissue regeneration
    • A61L2430/40Preparation and treatment of biological tissue for implantation, e.g. decellularisation, cross-linking
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S623/00Prosthesis, i.e. artificial body members, parts thereof, or aids and accessories therefor
    • Y10S623/915Method or apparatus for preparing biological material
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S623/00Prosthesis, i.e. artificial body members, parts thereof, or aids and accessories therefor
    • Y10S623/915Method or apparatus for preparing biological material
    • Y10S623/916Blood vessel
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S623/00Prosthesis, i.e. artificial body members, parts thereof, or aids and accessories therefor
    • Y10S623/915Method or apparatus for preparing biological material
    • Y10S623/918Heart

Abstract

The present invention relates, in general, to tissue decellularization and, in particular to a method of treating tissues, for example, heart valves, tendons and ligaments, so as to render them acellular and thereby limit mineralization and/or immunoreactivity upon implementation in vivo.

Description

    TECHNICAL FIELD
  • The present invention relates, in general, to tissue decellularization and, in particular to a method of treating tissues, for example, heart valves, ligaments and tendons, so as to render them acellular and thereby limit mineralization and/or immunoreactivity upon implantation in vivo. [0001]
  • BACKGROUND
  • Cardiac valve disorders can be serious and in fact are often fatal. Treatment may require replacement of the valve with a prosthetic valve—mechanical or bioprosthetic. Bioprosthetic valves typically include a leaflet portion and a vascular conduit portion, both generally of a biological material, and possibly a stent. [0002]
  • While bioprosthetic valves have a number of advantages over mechanical valves, including a lower risk of complications resulting from thrombus formation, they are associated with a higher risk of mineralization. This increased risk significantly limits the durability of the replacement valve. The present invention provides a method of rendering tissues, including heart valves, resistant to mineralization while preserving biomechanical properties of the tissue. The present invention also provides a method of reducing immunoreactivity of transplanted tissues which are not fixed by chemical or physical means, or combinations thereof, prior to implantation. [0003]
  • OBJECT AND SUMMARY OF THE INVENTION
  • It is a general object of the invention to provide a method treating tissue so as to limit mineralization and/or immunoreactivity post implantation. [0004]
  • It is another object of the invention to provide a method of decellularizing a tissue and thereby enhancing its durability and/or reducing its immunoreactivity. [0005]
  • It is a further object of the invention to provide a tissue, for example, a heart valve bioprosthesis, that retains mechanical integrity, is resistant to calcification and is characterized by reduced immunoreactivity upon implantation. [0006]
  • The foregoing objects are met by the present invention which provides a method of effecting decellularization of tissues, including heart valve tissues (eg leaflets and valve associated vascular conduit). The method comprises contacting the tissue to be decellularized with a hypotonic solution under conditions such that cell lysis occurs, and subsequently subjecting the tissue to nuclease treatment under conditions such that the tissue is rendered histologically acellular. [0007]
  • Further objects and advantages of the present invention will be clear from the description that follows. [0008]
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIGS. 1A and B show the effect of decellularization on the extensibility of and elastic modulus of aortic and pulmonary leaflets. [0009]
  • FIGS. 2A and B show the effect of decellularization on rates of stress-relaxation of aortic and pulmonary leaflets. [0010]
  • FIGS. 3A, B and C show the effect of decellularization on failure load, maximum stress and elastic modulus of aortic and pulmonary leaflets. [0011]
  • FIGS. 4A, B, C and D show the effect of decellularization on calcification of porcine heart aortic and pulmonary heart valve tissues. [0012]
  • DETAILED DESCRIPTION OF THE INVENTION
  • The present invention relates, in one embodiment, to a method of rendering a biological tissue acellular. The method comprises exposing the tissue to a hypotonic solution under conditions such that cell lysis results, and subjecting the resulting tissue to nuclease treatment so as to remove nucleic acids and associated phosphorous-containing groups which may bind calcium. Nuclease treatment effectively stops cell replication and protein synthesis. In a preferred aspect of this embodiment, the tissue is rendered essentially acellular, the term “essentially” meaning having at least 70% fewer cells than the naturally occurring biological material. The extent of decellularization can be determined histochemically, for example, by staining the tissue with hematoxylin and eosin using standard techniques. Immunohistochemical staining can also be used, for example, to visualize cell specific markers such as smooth muscle actin and histocompatibility antigens—an absence of such markers being a further indication of decellularization. [0013]
  • In accordance with the present method, the biological tissue is, preferably, first washed in a solution of a bioburden reducing agent, such as an antibiotic. The tissue can then be decellularized immediately or it can be cryopreserved. Cryopreserved tissue is thawed prior to decellularization under conditions such that the cryoprotectant is eliminated and toxicity resulting therefrom thereby avoided. Appropriate thawing conditions are well known in the art. The tissue (fresh or thawed cryopreserved) is then placed in hypotonic solution in order to effect cell lysis. Appropriate solutions include water or a solution having a solute (eg a salt such as NaCl) concentration of up to 80 milliosmolar (for example, a 10-20 or 20-40 mM NaCl solution). Lysis can be effected, for example, at a temperature in the range of 30°C. to 40°C., preferably 37°C., advantageously in an atmosphere of 5% CO[0014] 2, for example, for about 4 to 24 hours. The tissue is then transferred to a nuclease solution (eg DNAase- and/or RNAase-containing) and incubated, for example, at a temperature in the range of about 30°C. to 40°C., preferably 37°C., advantageously in an atmosphere of 5% CO2, for example, for about 4 to 24 hours. Subsequently, the tissue is transferred to a solution that can maintain tissue structural integrity, for example, a physiologically normal (isotonic) solution such as a cell culture medium, eg DMEM. Cell lysis can continue during maintenance of the tissue in the physiologically normal solution and thus the tissue can be removed from the lytic/nuclease solutions before 70% decellularization has been achieved.
  • Tissues that have been decellularized can be terminally sterilized using any of a variety of sterilants. For example, the tissue can be subjected to gamma irradiation, ethylene oxide, peracetic acid, β-propiolactone, povidone-iodine, or UV irradiation in the presence or absence of photosensitizers. Appropriate conditions for effecting terminal sterilization are well known in the art. [0015]
  • Biological tissues suitable for use in the present method include those appropriate for implantation into humans or animals. Tissues can be human or non-human (eg bovine, porcine or non-human primate) in origin. As indicated above, the tissues can be fresh or cryopreserved. In either case, the tissue is decellularized prior to any fixation. While the present invention is exemplified by reference to heart valve leaflets, the decellularization method is applicable to other tissues as well, including tendons, ligaments, facia, arteries, veins, diaphragm, pericardium, umbilical cords, dura mater or tympanic membranes. [0016]
  • Upon completion of decellularization, the biological tissue can be processed and/or fabricated as appropriate depending on the ultimate use of the tissue. Any fixation of the decellularized tissue can be effected using art-recognized techniques, including glutaraldehyde fixation. Unfixed tissue, however, can also be used. Unfixed tissue can be impregnated with any of a variety of agents including those that stimulate recellularization upon implantation of the decellularized tissue in vivo. Examples of such agents include growth factors, adhesion factors, such as glycosaminoglycans, and soluble extracellular matrix glycoproteins such as fibronectin, laminin, vitronectin, etc. Other agents that can be used include those that augment hemocompatability, thrombomodulators, and antibiotics. Appropriate impregnation techniques are known in the art. When the tissue is a heart valve, fabrication with a biological or non-biological stent can be effected using standard protocols. [0017]
  • Bioprostheses produced in accordance with the present invention can be used as replacements for defective tissues in mammals, particularly humans. Methods of effecting the replacement of, for example, heart valves, tendons, ligaments, vessels, etc., are well known in the art. [0018]
  • Tissue decellularized in accordance with the present invention is subject to less mineralization (eg calcification) in vivo than non-treated tissue. Decellularization also results in a tissue that is reduced in immunogenicity. [0019]
  • Certain aspects of the present invention are described in greater detail in the non-limiting Examples that follow. While the decellularization methodology of the present invention and that of U.S. Pat. No. 5,595,571 are distinct, it will be appreciated that certain details of that disclosure are equally applicable here, including source of biological tissues, methods of monitoring extent of decellularization and methods of processing and fabrication post decellularization. Accordingly, U.S. Pat. No. 5,595,571 is incorporated in its entirety by reference. [0020]
  • EXAMPLE I
  • Decellularization of Leaflets and Whole Values [0021]
  • The following solutions are utilized in the protocols that follow: [0022]
  • 1M Tris pH 7.6: To 80 ml deionized water add 11.21 gm Tris, adjust pH to 7.6 with 1N NaOH and bring volume to 100 ml and store at 4°C. [0023]
  • 1M CaCl[0024] 2: To 20 ml deionized water add 2.22 gm CaCl2 and store at 4°C.
  • 1M MgCl[0025] 2: To 10 ml deionized water add 2.033 gm MgCl2 and store at 4°C.
  • DNAse I Solution: To 4.95 ml sterile water add 5 ml glycerol (final conc 50%), 20 mg DNAse I (Sigma D5025) (final conc 2 mg/ml), and 50 μl 1M CaCl[0026] 2 (final conc 5 mM). Aliquot 1 ml to chilled labeled 1.5 ml microfuge tubes and store at −20°C.
  • RNASe A Solution: To 10 ml sterile water add 100 mg RNAse A, and mix to dissolve. Aliquot 500 μl of solution to each of 20 prechilled 1.5 ml microfuge tubes and store at −20° C. [0027]
  • Nuclease Solution: To 93.66 ml sterile water, add 4.8 ml 1M Tris pH 7.6 (final 48 mM), 288 μl 1M MgCl[0028] 2 (final conc 2.88 mM), 96 μl 1M CaCl2 (final conc 0.96 mM), filter sterilize using 0.2 micron filter, add 960 μl 2 mg/ml DNAse I (final conc 19.2 μg/ml) 192 μl 10 mg/ml RNAse A (final conc 19.2 μg/ml).
  • Decellularization of leaflets DAY 1
  • A valve is removed from a liquid nitrogen freezer and submerged in a 37°C. water bath for approximately 15 min. Under sterile conditions, the valve is removed from the packaging and placed in a sterile 7 oz. specimen cup with approximately 50 ml of lactate-ringer 5% dextrose (LRD5) solution for 15 min. at room temperature. The valve is dissected by making a single cut down the commisure located between the left and right coronary arteries. The valve is laid open with the mitral valve leaflet up, the left coronary leaflet to the left, the right coronary leaflet to the right, and the non-coronary leaflet in the middle. The leaflets are dissected free of the valve as close to the conduit wall as possible and placed in separate labeled 15 ml conical centrifuge tubes filled with 10 ml LRD5 solution for 10 minutes at room temperature. The leaflets are moved to second labeled 15 ml conical centrifuge tubes filled with 10 ml LRD5 solution and allowed to stand for 10 minutes at room temperature. The leaflets then are moved to third labeled 15 ml conical centrifuge tubes filled with 10 ml sterile water and placed in an incubator at 37° C. 5% CO[0029] 2 for 2 hours. The leaflets are placed in 6-well culture plates and weighted down with sterile glass rings. 5 ml nuclease solution is added to each well and the leaflets incubated overnight at 37°C. 5% CO2.
  • DAY 2
  • The nuclease solution is removed and 5 ml of DMEM is added to each well and the leaflets are returned to the incubator. [0030]
  • DAY 3-16
  • The medium is changed every other day for two weeks. [0031]
  • Alternative procedure for whole valves [0032]
  • If valves have been cryopreserved, they are thawed and washed as above; if valves are fresh, they are washed once in 80 ml of LRD5 for 15 minutes in a 7 oz sterile specimen cup. [0033]
  • After the valve is washed, it is transferred to a 7 oz sterile specimen cup containing about 80 ml of sterile H[0034] 2O and placed in the 37°C. 5% CO2 incubator for 4 hours.
  • The valve is removed to a 7 oz sterile specimen cup containing about 80 ml nuclease solution and returned to the incubator overnight. [0035]
  • DAY 2
  • The valve is removed to a 7 oz sterile specimen cup containing about 80 ml (ALT+) solution (containing netilmicin, 54 μg/ml;, lincomycin, 131 g/ml; cefotaxime, 145 μg/ml; vancomycin, 109 μg/ml; rifampin, 65 μg/ml; fluconazole, 100 μg/ml; and amphotericin B, 84 μg/ml). [0036]
  • DAY 3-16
  • The medium is changed every other day for two weeks using ALT+ solution for the first week and DMEM for the second. [0037]
  • The foregoing procedures are open culture procedures. Thus the specimen cup lids are loosened when placed in the incubator. [0038]
  • EXAMPLE II Experimental details
  • Porcine heart valves. Porcine hearts were obtained from market weight pigs (>120 kg). After rinsing in sterile phosphate buffered saline, the hearts were field dissected (apex removed) and shipped at 4°C. in sterile PBS. All hearts arrived within 24 hr of animal slaughter. Aortic and pulmonary valves were dissected as roots. These tissues were subjected to a bioburden reduction step of incubation in a mixture of antibiotics and antimycotics for 48 hr at 48°C. The disinfected tissues were either cryopreserved (10% (v/v) DMSO and 10% (v/v) fetal bovine serum, −1° C./min) or were decellularized by a procedure involving treatment with hypotonic medium followed by digestion with a mixture of deoxyribonuclease I and ribonuclease A. After 12 days, the decellularized valves were either cryopreserved as above or chemically fixed in 0.35% (w/v) glutaraldehyde at 2 mmHg in phosphate buffered saline (pH 7.4) for a total of 7 days; the low pressure fixation ensures maintenance of the natural crimp of the collagen matrix. The fixed tissues were not cryopreserved, but were stored in 0.35% glutaraldehyde solution. [0039]
  • Prior to any examination (calcification, biomechanics, histology), the cryopreserved tissues were thawed rapidly to prevent ice-recrystallization by immersion of the packaged tissue in a 37°C. water bath. Cryopreservation medium was eluted from the thawed valves with 500 ml of lactated-Ringers solution containing 5% dextrose. The glutaraldehyde-fixed tissues were washed three times each with 200 ml of normal saline. [0040]
  • In vivo static calcification. Calcification of treated tissues was assessed in vivo by subdermal implantation in rats. Weanling male, Sprague-Dawley rats were obtained from Charles Rivers Laboratories. After one week equilibration, animals averaged 136±18 g in weight. The heart valves were dissected to provide aortic and pulmonary leaflets and vascular conduit sections, each 0.5 cm square. With the rats under ketamine and xylazine (10 mg/kg and 5 mg/kg, respectively, IP) anesthesia, and following preparation of a sterile field, 2 cm diameter pouches were formed in the dorsal subcubitae, four per animal, and sections of tissues inserted. Incisions were closed with stainless steel staples. The rats were allowed to recover and were then permitted free access to food and water. Tissue samples were recovered at 1, 2, and 4 months post-implantation for determination of calcium content. [0041]
  • Method for calcium determination in tissue samples. Recovered tissues were washed in sterile calcium and magnesium-free phosphate buffered saline, three times 10 ml each. Wet weight was measured, and after mincing, the pieces were dried overnight in a centrifugal evaporator (Savant Speed-Vac). After recording dry weight the tissues were digested in 10 ml of 25% (v/v) HNO[0042] 3 for at least 24 hr at 70°C. An aliquot of the digest solution was diluted 10-fold in 0.2 N HCl containing 1% (w/v) lanthanum nitrate. Finally, calcium content was measured using a Perkin-Elmer 300 atomic absorption spectrometer calibrated with a certified calcium standard from SPEX Plasma Standards (Cat. PLCA2-3Y. Response in this system was linear between 0.2-20 μg/ml.
  • Biomechanics testing. Aortic and pulmonary leaflets were die cut in the circumferential dimension to provide “dog-bone”-shaped specimens, 0.5 cm wide at midsubstance. Thickness of each sample was derived from the average of three measurements taken with a low mass pin attached to a conductance circuit and digital caliper. Leaflets were mounted in specially designed clamps with a standard gauge length of 1 cm. All testing was carried out with the tissue in Hank's balanced salt solution maintained at 37±2° C. Each specimen was preconditioned to a load of 150 g until successive load-elongation curves were superimposable (−20 cycles). The following measurements were then taken: 1) low-load elongation to derive stress-strain relationships while imposing up to 150 g load on the tissue at an extension rate of 10 mm/min, a rate which reflects previously reported studies of leaflet biomechanics (Leesson-Dietrich et al, J. Heart Valve Disease 4:88 (1995)); 2) examination of viscoelastic properties of the specimens in a stress-relaxation study (tissue elongated to a load of 150 g and following residual loads for up to 1000 sec)—both the % of initial load remaining at these time points as well as the rate of stress-relaxation (i.e., the slope of the percent stress remaining versus time) were determined; and 3) ultimate uniaxial tensile testing to tissue failure. At least 8 specimens of each tissue type were examined. [0043]
  • Histochemistry. Samples of fresh and explanted tissues were immersed in 10% sucrose solution for 4-18 hr at 4°C. After brief fixation in 10% formalin, the pieces were placed in molds and frozen in OCT using a liquid nitrogen bath. Cryosections, 6-10 μm thick, were cut using an IEC cryostat (Needham Heights, Mass.). Sections were then stained either with hematoxylin and eosin or stained specifically for calcium according to the method of von Kossa (Theory and Practice of Histological Techniques, edited by Bancroft and Stephens, Churchill Livingstone, Edinburgh (1990)). Sections were viewed and photographed using a Nikon Optiphot microscope. [0044]
  • Statistics. Statistical differences in the group means of biomechanical parameters was assessed by independent t-tests. A p value of 0.05 was chosen as the level of significant differences. Calcium data were analyzed according to ANOVA testing carried out with the statistical program for the IBM-PC, SPSS-PC. [0045]
  • Results
  • Biomechanics. Low load testing—extensibility and low modulus. The biomechanical properties of strips of aortic and pulmonary porcine heart valve leaflets were compared between fresh-cryopreserved and decellularized-cryopreserved tissues. Fresh aortic and pulmonary leaflets were found to have significant differences in extensibility; pulmonary leaflets had extension 2.3-fold greater than aortic leaflets (p<0.01)). However, the elastic modulus of these tissues were not different pre-decellularization (10.6±1.1 vs. 9.15±0.64, p=0.255, FIG. 1). With decellularization, the extensibility of the two leaflet type became indistinguishable (30.4±2.5 vs. 30.2±3.3, p=0.981). The elastic modulus of the aortic leaflets was unchanged by decellularization (p=ns (not significant)), as compared to the fresh tissue). In contrast, pulmonary leaflet tissues was markedly stiffened by decellularization, with the elastic modulus rising by 660%, (p=<0.05). As a result, the elastic modulus of decellularized pulmonary tissue was 550% greater than that of the decellularized aortic leaflet. [0046]
  • Stress-relaxation testing. The initial (10 sec) and the final (1,000 sec) rates of stress-relaxation for fresh aortic and pulmonary leaflets were comparable and not statistically different (p=0.103 and p=0.115, respectively, FIG. 2). For decellularized tissues, only the initial rate of stress-relaxation or aortic leaflets was obtained; this was no different from the fresh tissue value. The increased stiffening of the pulmonary leaflets with decellularization which was observed with low-load testing was reflected by a higher final level of stress remaining (increase from 64.1±2.18% to 81.5±2.5%). The relaxation slope for the pulmonary leaflets were reciprocally changed by decellularization, decreasing from 9.8±0.8 in the fresh tissue to 4.7±1.5 in the treated tissue. [0047]
  • Ultimate tensile testing—failure load, maximum stress, and elastic modulus (FIG. 3). In fresh tissues the aortic leaflets failed a twice the load as did the pulmonary valve tissue (p<0.001). However, there was no statistical difference maximum stress at failure of the aortic and pulmonary leaflets (8.0±1.2 MPa vs. 6.0±0.9, p=0.202). As well, the moduli of the fresh leaflets were not statistically different (p=0.333). [0048]
  • Decellularized aortic leaflets failed at the same load and maximum stress as did the fresh tissue. The failure load of pulmonary leaflets rose slightly but not significantly, but there was almost a tripling of the stress at failure. [0049]
  • The stiffening of pulmonary leaflets observed with load testing was again reflected when the tissue was loaded to failure. The modules of pulmonary leaflets taken to failure increased 2.6-fold after decellularization; in contrast, the elastic modules of the decellularized aortic leaflets declined slightly (45.5±6.2 MPa vs. 38.3±5.2 Mpa). [0050]
  • Tissue calcification. The kinetics of calcification of porcine heart valve tissues at 1, 2, and 4 months of implantation are presented in FIG. 4. Glutaraldehyde-fixed porcine pulmonary heart valve tissues appeared especially prone to calcify in the subdermal rat model. The pulmonary leaflets and vascular conduit calcified more rapidly than their aortic valve counterparts, the fixed pulmonary leaflets calcifying most rapidly of all tissues examined. Furthermore, glutaraldehyde-fixed pulmonary leaflets attained the highest tissue content of calcium over the four months of subcutaneous implantation. In general, the fixed vascular conduits calcified more slowly than the leaflets from the same valve type and the final calcium content was significantly lower (p<0.05 for both aortic and pulmonary valves) at 4 months. [0051]
  • The impact of depopulation on heart valve calcification seen as a slowing of the calcification of fixed or non-fixed tissue (pulmonary leaflet) or a plateauing of calcification after two months of implantation (aortic leaflet, aortic conduit, pulmonary artery). The plateau phenomenon was seen in either the unfixed tissues or in those which were decellularized prior to glutaraldehyde fixation. No statistically significant difference in the calcification of aortic conduit was found among the treatment groups over the 4 months of implantation. Calcification of decellularized aortic conduit proceeded more quickly than fixed tissue for the first 2 months of implant, and then leveled off while fixed conduit calcium content continued to rise. An attenuating effect on the increase in pulmonary artery calcium content was also observed relative to either fixed tissue group. [0052]
  • Aortic and pulmonary leaflets had somewhat different responses to decellularization. Decellularization of aortic leaflets with subsequent fixation resulted in lower calcium content (73±17 mg Ca[0053] 2+/g tissue) than aortic leaflets which were not fixed (121±8 mg/g, p<0.05). Although tissue was not available from the 4 month time point, in pulmonary leaflets, the decellularized tissue per se tended to have lower calcium content (152±5 vs. 101±34 mg/g at 2 months of implantation).
  • Histologic examinations. Areas of decellularized porcine aortic leaflet at 1 month can be shown free of endogenous cells within the tissue matrix as well as having no deposits. Since measured tissue calcium in this group was 60±14 mg/g, calcific deposits were found only in localized areas. When examined further using von Kossa's stain, such areas were evident. Within these areas calcium deposits appeared in association with nonspecific structures. In contrast, the early calcification of nondecellularized glutaraidehdye-fixed tissues was always associated with cell nuclei. The increasing extent of involvement of the leaflet tissue with time of implant is evident from a 1, 2, and 4 month sequence. The midsubstance of the leaflets calcified early, while the margins calcified later. In either the aortic or pulmonary valve vascular components, calcified areas typically remained at the periphery of the implant, and only infrequently did tissues show evidence of mineralization of the midsubstance of the implant. [0054]
  • All documents cited above are hereby incorporated in their entirety by reference. [0055]
  • One skilled in the art will appreciate from a reading of this disclosure that various changes in form and detail can be made without departing from the true scope of the invention. [0056]

Claims (15)

    What is claimed is:
  1. 1. A method of producing a decellularized tissue comprising:
    i) contacting a biological tissue with a hypotonic solution under conditions such that lysis of cells of said tissue is effected, and
    ii) contacting the tissue resulting from step (i) with nuclease under conditions such that nucleic acid is degraded,
    said decellularized tissue thereby being produced.
  2. 2. The method according to
    claim 1
    further comprising contacting the decellularized tissue with a physiologically isotonic solution.
  3. 3. The method according to
    claim 1
    further comprising fixing said decellularized tissue.
  4. 4. The method according to
    claim 1
    wherein said decellularized tissue is at least 70% decellularized.
  5. 5. The method according to
    claim 1
    wherein the tissue is a mammalian tissue.
  6. 6. The method according to
    claim 1
    wherein the tissue is a heart valve, tendon, ligament, artery, vein, diaphragm, pericardium, umbilical cord, facia, dura mater, tympanic membrane, or portion thereof.
  7. 7. The method according to
    claim 6
    wherein said tissue is a heart valve.
  8. 8. A decellularized tissue produced according to the method of
    claim 1
    .
  9. 9. The tissue according to
    claim 8
    wherein said tissue is a heart valve, tendon, ligament, artery, vein, diaphragm, pericardium, umbilical cord, facia, dura mater, tympanic membrane, or portion thereof.
  10. 10. The tissue according to
    claim 9
    wherein said tissue is a heart valve.
  11. 11. The tissue according to
    claim 8
    wherein the tissue is at least 70% decellularized.
  12. 12. The tissue according to
    claim 8
    wherein the tissue is fixed.
  13. 13. A method of mitigating mineralization of a biological tissue transplant comprising:
    i) contacting a biological tissue with a hypotonic solution under conditions such that lysis of cells of said biological tissue is effected, and
    ii) contacting the tissue resulting from step (i) with nuclease under conditions such that nucleic acid is degraded,
    wherein the tissue resulting from step (ii) is decellularized and said mitigation is thereby effected.
  14. 14. The method according to
    claim 13
    wherein mineralization is mitigated by at least 30 percent relative to non-decellularized tissue.
  15. 15. A method of reducing the immunogenicity of a biological tissue transplant comprising:
    i) contacting a biological tissue with a hypotonic solution under conditions such that lysis of cells of said biological tissue is effected, and
    ii) contacting the tissue resulting from step (i) with nuclease under conditions such that nucleic acid is degraded,
    wherein the tissue resulting from step (ii) is decellularized and said reduction in immunogenicity is thereby effected.
US09735522 1997-04-11 2000-12-14 Tissue decellularization Abandoned US20010000804A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US83885297 true 1997-04-11 1997-04-11
US09735522 US20010000804A1 (en) 1997-04-11 2000-12-14 Tissue decellularization

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09735522 US20010000804A1 (en) 1997-04-11 2000-12-14 Tissue decellularization
US10394576 US7318998B2 (en) 1997-04-11 2003-03-24 Tissue decellularization

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US83885297 Continuation 1997-04-11 1997-04-11

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10394576 Continuation US7318998B2 (en) 1997-04-11 2003-03-24 Tissue decellularization

Publications (1)

Publication Number Publication Date
US20010000804A1 true true US20010000804A1 (en) 2001-05-03

Family

ID=25278218

Family Applications (2)

Application Number Title Priority Date Filing Date
US09735522 Abandoned US20010000804A1 (en) 1997-04-11 2000-12-14 Tissue decellularization
US10394576 Expired - Lifetime US7318998B2 (en) 1997-04-11 2003-03-24 Tissue decellularization

Family Applications After (1)

Application Number Title Priority Date Filing Date
US10394576 Expired - Lifetime US7318998B2 (en) 1997-04-11 2003-03-24 Tissue decellularization

Country Status (8)

Country Link
US (2) US20010000804A1 (en)
EP (1) EP0987998B1 (en)
JP (1) JP2001520542A (en)
CA (1) CA2286655C (en)
DE (1) DE69827001T2 (en)
DK (1) DK0987998T3 (en)
ES (1) ES2231980T3 (en)
WO (1) WO1998046165A1 (en)

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6630001B2 (en) * 1998-06-24 2003-10-07 International Heart Institute Of Montana Foundation Compliant dehyrated tissue for implantation and process of making the same
US20040209235A1 (en) * 2002-12-11 2004-10-21 Steven Goldstein Radical retardant cryopreservation solutions
US20050043819A1 (en) * 2002-09-27 2005-02-24 Board Of Regents, The University Of Texas System Cell-free tissue replacement for tissue engineering
US20050191281A1 (en) * 2000-01-28 2005-09-01 Cryolife, Inc. Tissue graft
US20060275377A1 (en) * 2005-03-16 2006-12-07 Musculoskeletal Transplan Foundation Soft tissue processing
US20070162119A1 (en) * 2006-01-07 2007-07-12 Medical College Of Georgia Research Institute, Inc. Tympanic membrane prosthesis and a tool for manufacturing the prosthesis
US20070255423A1 (en) * 1998-09-21 2007-11-01 Carpentier Alain F Treating biological tissues to mitigate post-implantation calcification
US20080102439A1 (en) * 2006-10-27 2008-05-01 Bin Tian Biological tissue for surgical implantation
US20080302372A1 (en) * 2007-06-11 2008-12-11 Edwards Lifesciences Corporation Methods for pre-stressing and capping bioprosthetic tissue
US20090164005A1 (en) * 2007-12-21 2009-06-25 Edwards Lifesciences Corporation Capping Bioprosthetic Tissue to Reduce Calcification
WO2010033860A1 (en) * 2008-09-18 2010-03-25 The Curators Of The University Of Missouri Bionanocomposite for tissue regeneration and soft tissue repair
US20100112543A1 (en) * 2005-03-16 2010-05-06 Manh-Dan Ngo Processing soft tissue, methods and compositions related thereto
US20100233669A1 (en) * 2009-03-11 2010-09-16 Cryolife, Inc. Bioburden-reducing antibiotic composition and method of use
US8377143B2 (en) 2010-07-06 2013-02-19 Cryolife, Inc. Tissue implants for implantation and methods for preparing the same
US8475827B2 (en) 2010-07-06 2013-07-02 Cryolife, Inc. Tissue implants for implantation and methods for preparing the same
US8632608B2 (en) 2002-01-03 2014-01-21 Edwards Lifesciences Corporation Treatment of bioprosthetic tissues to mitigate post implantation calcification
US8753406B2 (en) 2010-08-31 2014-06-17 Zimmer Inc. Osteochondral graft delivery device and uses thereof
US8846390B2 (en) 2010-03-23 2014-09-30 Edwards Lifesciences Corporation Methods of conditioning sheet bioprosthetic tissue
US8906601B2 (en) 2010-06-17 2014-12-09 Edwardss Lifesciences Corporation Methods for stabilizing a bioprosthetic tissue by chemical modification of antigenic carbohydrates
US20150245907A1 (en) * 2011-05-27 2015-09-03 Robert G. Matheny Extracellular Matrix Material Valve Conduit and Methods of Making Thereof
US9351829B2 (en) 2010-11-17 2016-05-31 Edwards Lifesciences Corporation Double cross-linkage process to enhance post-implantation bioprosthetic tissue durability
US9615922B2 (en) 2013-09-30 2017-04-11 Edwards Lifesciences Corporation Method and apparatus for preparing a contoured biological tissue

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69817863T2 (en) 1997-10-31 2004-07-15 Children's Medical Center Corp., Boston bladder reconstruction
US6254564B1 (en) 1998-09-10 2001-07-03 Percardia, Inc. Left ventricular conduit with blood vessel graft
US6576265B1 (en) 1999-12-22 2003-06-10 Acell, Inc. Tissue regenerative composition, method of making, and method of use thereof
US6479064B1 (en) * 1999-12-29 2002-11-12 Children's Medical Center Corporation Culturing different cell populations on a decellularized natural biostructure for organ reconstruction
USRE45130E1 (en) 2000-02-28 2014-09-09 Jenavalve Technology Gmbh Device for fastening and anchoring cardiac valve prostheses
DE10010073B4 (en) 2000-02-28 2005-12-22 Ferrari, Markus, Dr.med. Dr.disc.pol. Anchor for implantable heart valve prostheses
JP2003531685A (en) * 2000-04-28 2003-10-28 エモリー ユニバーシテイ Decellularized vascular prosthesis
FR2828263B1 (en) 2001-08-03 2007-05-11 Philipp Bonhoeffer The implantation device of an implant and method of implantation of the device
US8308797B2 (en) 2002-01-04 2012-11-13 Colibri Heart Valve, LLC Percutaneously implantable replacement heart valve device and method of making same
US20040176855A1 (en) * 2003-03-07 2004-09-09 Acell, Inc. Decellularized liver for repair of tissue and treatment of organ deficiency
US20050025838A1 (en) 2003-06-25 2005-02-03 Badylak Stephen F. Conditioned compositions for tissue restoration
DE102005003632A1 (en) 2005-01-20 2006-08-17 Ferrari, Markus, Dr.med. Dr.disc.pol. Catheter for trans-vascular implantation of prosthetic heart valves
JP2009505752A (en) * 2005-08-26 2009-02-12 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ Decellularization and recellularization of organs and tissues
DE102005051849B4 (en) 2005-10-28 2010-01-21 JenaValve Technology Inc., Wilmington A device for implantation and fixation of prosthetic heart valves
DE102005052628B4 (en) 2005-11-04 2014-06-05 Jenavalve Technology Inc. Self-expanding, flexible wire mesh with integrated valve prosthesis for the transvascular cardiac valve replacement and a system comprising such a device and a delivery catheter
US20070213813A1 (en) * 2005-12-22 2007-09-13 Symetis Sa Stent-valves for valve replacement and associated methods and systems for surgery
US9138315B2 (en) 2007-04-13 2015-09-22 Jenavalve Technology Gmbh Medical device for treating a heart valve insufficiency or stenosis
US7896915B2 (en) 2007-04-13 2011-03-01 Jenavalve Technology, Inc. Medical device for treating a heart valve insufficiency
RU2535365C2 (en) 2007-05-29 2014-12-10 Кристофер Б РЕЙД Methods of obtainment and application of multipotent cell populations
US9580688B2 (en) 2007-06-08 2017-02-28 Wake Forest University Health Sciences Kidney structures and methods of forming the same
WO2008153970A1 (en) 2007-06-08 2008-12-18 Wake Forest University Health Sciences Selective cell therapy for the treatment of renal failure
US8398704B2 (en) 2008-02-26 2013-03-19 Jenavalve Technology, Inc. Stent for the positioning and anchoring of a valvular prosthesis in an implantation site in the heart of a patient
US8465540B2 (en) 2008-02-26 2013-06-18 Jenavalve Technology, Inc. Stent for the positioning and anchoring of a valvular prosthesis
US9044318B2 (en) 2008-02-26 2015-06-02 Jenavalve Technology Gmbh Stent for the positioning and anchoring of a valvular prosthesis
WO2011104269A1 (en) 2008-02-26 2011-09-01 Jenavalve Technology Inc. Stent for the positioning and anchoring of a valvular prosthesis in an implantation site in the heart of a patient
US8317858B2 (en) 2008-02-26 2012-11-27 Jenavalve Technology, Inc. Stent for the positioning and anchoring of a valvular prosthesis in an implantation site in the heart of a patient
US9168130B2 (en) 2008-02-26 2015-10-27 Jenavalve Technology Gmbh Stent for the positioning and anchoring of a valvular prosthesis in an implantation site in the heart of a patient
US9044305B2 (en) * 2008-04-03 2015-06-02 Cook Medical Technologies Llc Self cleaning devices, systems and methods of use
US8709096B2 (en) * 2008-04-29 2014-04-29 Proxy Biomedical Limited Tissue repair implant
US8468667B2 (en) 2009-05-15 2013-06-25 Jenavalve Technology, Inc. Device for compressing a stent
US8298586B2 (en) 2009-07-22 2012-10-30 Acell Inc Variable density tissue graft composition
US8652500B2 (en) 2009-07-22 2014-02-18 Acell, Inc. Particulate tissue graft with components of differing density and methods of making and using the same
FR2951549B1 (en) 2009-10-15 2013-08-23 Olivier Schussler Method for obtaining implantable medical bioprosthesis
US9566369B2 (en) 2010-02-26 2017-02-14 Decell Technologies Inc. Methods for tissue decellularization
US20110288626A1 (en) 2010-05-20 2011-11-24 Helmut Straubinger Catheter system for introducing an expandable heart valve stent into the body of a patient, insertion system with a catheter system and medical device for treatment of a heart valve defect
CN103002833B (en) 2010-05-25 2016-05-11 耶拿阀门科技公司 Artificial heart valve and includes an artificial heart valve and the stent delivery catheter endoprosthesis
JP6005168B2 (en) 2011-10-21 2016-10-12 イエナバルブ テクノロジー インク Insertion system and heart valve defects therapeutic medical device comprising expandable heart valve stent introducer catheter system into a patient's body, the catheter system
CN102350008A (en) 2011-10-25 2012-02-15 微创医疗器械(上海)有限公司 Method for treating animal-derived collagen fiber material
EP2811939B8 (en) * 2012-02-10 2017-11-15 CVDevices, LLC Products made of biological tissues for stents and methods of manufacturing
US9670457B2 (en) 2012-05-08 2017-06-06 Stem Cell Reserve Lp Stem cells and matrix from cord tissue
WO2013171007A1 (en) 2012-05-16 2013-11-21 Jenavalve Technology Gmbh Catheter delivery system for introducing an expandable heart valve prosthesis and medical device for the treatment of a heart valve defect
GB201215725D0 (en) * 2012-09-04 2012-10-17 Univ Leeds Composite connective tissue and bone implants
US9795638B1 (en) * 2013-03-16 2017-10-24 BioDlogics, LLC Cardiothoracic construct and methods of use
CN105491978A (en) 2013-08-30 2016-04-13 耶拿阀门科技股份有限公司 Radially collapsible frame for a prosthetic valve and method for manufacturing such a frame
US9999707B2 (en) 2014-03-04 2018-06-19 University of Pittsburgh—of the Commonwealth System of Higher Education Method for decellularization of tissue

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8618374D0 (en) * 1986-07-28 1986-09-03 Hsc Res Dev Corp Biological vascular prostheses
ES2219660T3 (en) * 1994-03-14 2004-12-01 Cryolife, Inc Methods of preparing tissue for implantation.
US5595571A (en) * 1994-04-18 1997-01-21 Hancock Jaffe Laboratories Biological material pre-fixation treatment

Cited By (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6630001B2 (en) * 1998-06-24 2003-10-07 International Heart Institute Of Montana Foundation Compliant dehyrated tissue for implantation and process of making the same
US8236241B2 (en) 1998-09-21 2012-08-07 Edwards Lifesciences Corporation Treating biological tissues to mitigate post-implantation calcification
US20070255423A1 (en) * 1998-09-21 2007-11-01 Carpentier Alain F Treating biological tissues to mitigate post-implantation calcification
US20100285587A1 (en) * 2000-01-28 2010-11-11 Cryolife, Inc. Tissue Graft
US20050191281A1 (en) * 2000-01-28 2005-09-01 Cryolife, Inc. Tissue graft
US7763081B2 (en) 2000-01-28 2010-07-27 Cryolife, Inc. Tissue graft
US8632608B2 (en) 2002-01-03 2014-01-21 Edwards Lifesciences Corporation Treatment of bioprosthetic tissues to mitigate post implantation calcification
US8758794B2 (en) 2002-09-27 2014-06-24 Board Of Regents, The University Of Texas System Cell-free tissue replacement for tissue engineering
US20050043819A1 (en) * 2002-09-27 2005-02-24 Board Of Regents, The University Of Texas System Cell-free tissue replacement for tissue engineering
US20090030269A1 (en) * 2002-09-27 2009-01-29 Board Of Regents, The University Of Texas System Cell-free tissue replacement for tissue engineering
US9597429B2 (en) 2002-09-27 2017-03-21 Board Of Regents, The University Of Texas System Cell-free tissue replacement for tissue engineering
US7402319B2 (en) 2002-09-27 2008-07-22 Board Of Regents, The University Of Texas System Cell-free tissue replacement for tissue engineering
US7129035B2 (en) 2002-12-11 2006-10-31 Cryolife, Inc. Method of preserving tissue
US20040209235A1 (en) * 2002-12-11 2004-10-21 Steven Goldstein Radical retardant cryopreservation solutions
US8557581B2 (en) 2005-03-16 2013-10-15 Musculoskeletal Transplant Foundation Soft tissue processing
US20100304487A1 (en) * 2005-03-16 2010-12-02 Musculoskeletal Transplant Foundation Soft tissue processing
US20100112543A1 (en) * 2005-03-16 2010-05-06 Manh-Dan Ngo Processing soft tissue, methods and compositions related thereto
US7723108B2 (en) * 2005-03-16 2010-05-25 Musculoskeletal Transplant Foundation Soft tissue processing
US20060275377A1 (en) * 2005-03-16 2006-12-07 Musculoskeletal Transplan Foundation Soft tissue processing
US20070162119A1 (en) * 2006-01-07 2007-07-12 Medical College Of Georgia Research Institute, Inc. Tympanic membrane prosthesis and a tool for manufacturing the prosthesis
US9918832B2 (en) 2006-10-27 2018-03-20 Edwards Lifesciences Corporation Biological tissue for surgical implantation
US20080102439A1 (en) * 2006-10-27 2008-05-01 Bin Tian Biological tissue for surgical implantation
US8007992B2 (en) 2006-10-27 2011-08-30 Edwards Lifesciences Corporation Method of treating glutaraldehyde-fixed pericardial tissue with a non-aqueous mixture of glycerol and a C1-C3 alcohol
US20080302372A1 (en) * 2007-06-11 2008-12-11 Edwards Lifesciences Corporation Methods for pre-stressing and capping bioprosthetic tissue
US9101691B2 (en) 2007-06-11 2015-08-11 Edwards Lifesciences Corporation Methods for pre-stressing and capping bioprosthetic tissue
US8357387B2 (en) 2007-12-21 2013-01-22 Edwards Lifesciences Corporation Capping bioprosthetic tissue to reduce calcification
US20090164005A1 (en) * 2007-12-21 2009-06-25 Edwards Lifesciences Corporation Capping Bioprosthetic Tissue to Reduce Calcification
US7972376B1 (en) 2007-12-21 2011-07-05 Edwards Lifesciences Corporation Capping bioprosthetic tissue to reduce calcification
US8748490B2 (en) 2007-12-21 2014-06-10 Edwards Lifesciences Corporation Capping bioprosthetic tissue to reduce calcification
US9029418B2 (en) 2007-12-21 2015-05-12 Edwards Lifesciences Corporation Capping bioprosthetic tissue to reduce calcification
WO2010033860A1 (en) * 2008-09-18 2010-03-25 The Curators Of The University Of Missouri Bionanocomposite for tissue regeneration and soft tissue repair
US20100106233A1 (en) * 2008-09-18 2010-04-29 The Curators Of The University Of Missouri Bionanocomposite for tissue regeneration and soft tissue repair
US20100233669A1 (en) * 2009-03-11 2010-09-16 Cryolife, Inc. Bioburden-reducing antibiotic composition and method of use
US9492230B2 (en) 2010-03-23 2016-11-15 Edwards Lifesciences Corporation Methods of conditioning sheet bioprosthetic tissue
US8846390B2 (en) 2010-03-23 2014-09-30 Edwards Lifesciences Corporation Methods of conditioning sheet bioprosthetic tissue
US9498287B2 (en) 2010-03-23 2016-11-22 Edwards Lifesciences Corporation Methods of conditioning sheet bioprosthetic tissue
US10092399B2 (en) 2010-03-23 2018-10-09 Edwards Lifesciences Corporation Methods of conditioning sheet bioprosthetic tissue
US9498288B2 (en) 2010-03-23 2016-11-22 Edwards Lifesciences Corporation Methods of conditioning sheet bioprosthetic tissue
US8906601B2 (en) 2010-06-17 2014-12-09 Edwardss Lifesciences Corporation Methods for stabilizing a bioprosthetic tissue by chemical modification of antigenic carbohydrates
US8377143B2 (en) 2010-07-06 2013-02-19 Cryolife, Inc. Tissue implants for implantation and methods for preparing the same
US8883408B2 (en) 2010-07-06 2014-11-11 Cryolife, Inc. Tissue implants for implantation and methods of preparing the same
US8475827B2 (en) 2010-07-06 2013-07-02 Cryolife, Inc. Tissue implants for implantation and methods for preparing the same
US8753406B2 (en) 2010-08-31 2014-06-17 Zimmer Inc. Osteochondral graft delivery device and uses thereof
US9351829B2 (en) 2010-11-17 2016-05-31 Edwards Lifesciences Corporation Double cross-linkage process to enhance post-implantation bioprosthetic tissue durability
US9241789B2 (en) * 2011-05-27 2016-01-26 Cormatrix Cardiovascular, Inc. Extracellular matrix material valve conduit and methods of making thereof
US20150245907A1 (en) * 2011-05-27 2015-09-03 Robert G. Matheny Extracellular Matrix Material Valve Conduit and Methods of Making Thereof
US9615922B2 (en) 2013-09-30 2017-04-11 Edwards Lifesciences Corporation Method and apparatus for preparing a contoured biological tissue

Also Published As

Publication number Publication date Type
EP0987998A1 (en) 2000-03-29 application
WO1998046165A1 (en) 1998-10-22 application
EP0987998A4 (en) 2002-05-22 application
ES2231980T3 (en) 2005-05-16 grant
DE69827001D1 (en) 2004-11-18 grant
DK0987998T3 (en) 2005-01-17 grant
CA2286655C (en) 2009-02-24 grant
JP2001520542A (en) 2001-10-30 application
CA2286655A1 (en) 1998-10-22 application
US7318998B2 (en) 2008-01-15 grant
US20030228692A1 (en) 2003-12-11 application
DE69827001T2 (en) 2005-09-08 grant
EP0987998B1 (en) 2004-10-13 grant

Similar Documents

Publication Publication Date Title
US6852339B2 (en) Tissue regenerative composition, method of making, and method of use thereof
US6214055B1 (en) Method and kit for rapid preparation of autologous tissue medical devices
US6352708B1 (en) Solution and method for treating autologous tissue for implant operation
US4402697A (en) Method for inhibiting mineralization of natural tissue during implantation
US6861211B2 (en) Stabilization of implantable bioprosthetic devices
Chang et al. In vivo evaluation of cellular and acellular bovine pericardia fixed with a naturally occurring crosslinking agent (genipin)
US5558875A (en) Method of preparing collagenous tissue
US4323358A (en) Method for inhibiting mineralization of natural tissue during implantation
US5674298A (en) Calcification-resistant bioprosthetic tissue and methods of making same
US7189259B2 (en) Tissue material and process for bioprosthesis
Ferrans et al. Structural changes in glutaraldehyde-treated porcine heterografts used as substitute cardiac valves: transmission and scanning electron microscopic observations in 12 patients
US6878168B2 (en) Treatment of bioprosthetic tissues to mitigate post implantation calcification
US5645587A (en) Prevention of calcification and degeneration of biological tissue grafts for implantation in humans
US6008292A (en) Method for inhibiting calcification of aldehyde-fixed bioprosthetic materials
US5746775A (en) Method of making calcification-resistant bioprosthetic tissue
Liao et al. Effects of decellularization on the mechanical and structural properties of the porcine aortic valve leaflet
US6471723B1 (en) Biocompatible prosthetic tissue
US6132986A (en) Tissue crosslinking for bioprostheses using activated difunctional or polyfunctional acids
US20050260612A1 (en) Chemical treatment for removing cellular and nuclear material from naturally occurring extracellular matrix-based biomaterials
US6743574B1 (en) Process for devitalizing soft-tissue engineered medical implants, and devitalized soft-tissue medical implants produced
US4776853A (en) Process for preparing biological mammalian implants
Ketchedjian et al. Recellularization of decellularized allograft scaffolds in ovine great vessel reconstructions
Abraham et al. Evaluation of the porcine intestinal collagen layer as a biomaterial
US5447536A (en) Method for fixation of biological tissue
US5762600A (en) Blood contact surfaces employing natural subendothelial matrix and methods for making and using the same

Legal Events

Date Code Title Description
AS Assignment

Owner name: WELLS FARGO FOOTHILL, INC., GEORGIA

Free format text: SECURITY AGREEMENT;ASSIGNORS:CRYOLIFE, INC.;CRYOLIFE TECHNOLOGY, INC.;REEL/FRAME:016256/0042

Effective date: 20050208

AS Assignment

Owner name: CRYOLIFE, INC., GEORGIA

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:WELLS FARGO FOOTHILL, INC.;REEL/FRAME:020580/0036

Effective date: 20080208